SLAMF6 and exocrine pancreatic carcinoma: Suitable animal models meant to be employed in follow-up studies on in vivo testing of CAR T cells co-expressing soluble SLAMF6 would comprise an orthotopic xenograft model of pancreas carcinoma, such as published by Ma et al. [35], in conjunction with a syngeneic mouse model harboring a fully preserved tumor microenvironment, such as the B16 melanoma model [44].